Home › Funds › Two Sigma Investments › BBIO

Two Sigma Investments position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Two Sigma Investments reported holding 3,660,083 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$240.8M, representing 0.34% of its reported portfolio and ranking #45 among its reported holdings. Two Sigma Investments has disclosed BBIO holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

Latest position (Q3 2026)3.66M sh
Reported value held$240.83M
Portfolio Weight0.34%
First reportedQ3 2021
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Two Sigma Investments's BBIO position evolved

Two Sigma Investments first disclosed a stake in BBIO in Q3 2021 at 46,722 shares (US$2.2M). The position peaked in Q3 2026 at 3,660,083 shares, worth US$240.8M. Across 21 filings, Two Sigma Investments increased the stake 8 time(s), trimmed it 11 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 3,660,083 shares valued at US$240.8M — an increase of 3,650,083 shares quarter over quarter.. Notable position changes include a 1197% increase in Q4 2021 (shares fell 39% over the following quarter), a 476% increase in Q3 2022 (shares fell 23% over the following quarter), a 36501% increase in Q3 2026 (shares rose 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 46.72K $2.19M New
Q4 2021 606.19K $10.11M Add
Q1 2022 509.55K $5.17M Reduce
Q2 2022 151.26K $1.37M Reduce
Q3 2022 871.21K $8.66M Add
Q4 2022 651.21K $4.96M Reduce
Q1 2023 779.54K $12.92M Add
Q2 2023 740.39K $12.73M Reduce
Q3 2023 1.28M $33.68M Add
Q4 2023 966.80K $39.03M Reduce
Q1 2024 744.60K $23.02M Reduce
Q2 2024 565.45K $14.32M Reduce
Q3 2024 381.24K $9.71M Reduce
Q4 2024 238.54K $6.55M Reduce
Q1 2025 843.32K $29.15M Add
Q2 2025 2.34M $101.00M Add
Q3 2025 2.33M $120.97M Hold
Q4 2025 1.95M $148.93M Reduce
Q1 2026 3.12M $231.74M Add
Q2 2026 10.00K $744.80K Reduce
Q3 2026 3.66M $240.83M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 41 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Two Sigma Investments held BBIO?

Two Sigma Investments has disclosed BBIO holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

What is Two Sigma Investments's current position in BBIO?

As of Q3 2026, Two Sigma Investments holds 3.66M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $240.83M, representing 0.34% of its reported portfolio and ranking #45.

Has Two Sigma Investments been buying or selling BBIO?

In the latest 13F filing (Q3 2026), Two Sigma Investments increased its position in BBIO. The position peaked in Q3 2026 at 3.66M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.